KEGG   DRUG: Pegaptanib sodium
Entry
D05386                      Drug                                   
Name
Pegaptanib sodium (JAN/USAN);
Macugen (TN)
Formula
C294H342F13N107O188P28(C2H4O)n. 28Na
Remark
ATC code: S01LA03
Efficacy
Aging-related macular degeneration therapeutic agent, Angiogenesis inhibitor, Anti-VEGF aptamer
  Type
RNA aptamer
Comment
Pegaptanib inhibits VEGF165 selectively.
Treatment of age-related macular degeneration disease
Target
VEGFA [HSA:7422] [KO:K05448]
  Pathway
hsa04370  VEGF signaling pathway
hsa05200  Pathways in cancer
Brite
Anatomical Therapeutic Chemical (ATC) classification [BR:br08303]
 S SENSORY ORGANS
  S01 OPHTHALMOLOGICALS
   S01L OCULAR VASCULAR DISORDER AGENTS
    S01LA Antineovascularisation agents
     S01LA03 Pegaptanib
      D05386  Pegaptanib sodium (JAN/USAN)
Target-based classification of drugs [BR:br08310]
 Cytokines and receptors
  Cytokines
   Growth factors (RTK-binding)
    VEGFA
     D05386  Pegaptanib sodium (JAN/USAN)
New drug approvals in the USA [br08319.html]
 New molecular entities and new therapeutic biological products
  D05386
New drug approvals in Europe [br08329.html]
 European public assessment reports (EPAR) authorised medicine
  D05386
New drug approvals in Japan [br08318.html]
 Drugs with new active ingredients
  D05386
New drug approvals in the USA, Europe and Japan [br08328.html]
 Approval dates by FDA, EMA and PMDA
  D05386
Other DBs
CAS: 222716-86-1
PubChem: 47207062
NIKKAJI: J2.229.653A
LinkDB

» Japanese version   » Back

DBGET integrated database retrieval system